Phil Nadeau
Stock Analyst at TD Cowen
(2.70)
# 1,835
Out of 4,820 analysts
22
Total ratings
42.86%
Success rate
32.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Buy | n/a | $6.43 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $63.76 | +1.94% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $118.84 | +131.40% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $63.32 | +89.51% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $493.84 | +1.25% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $18.01 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $39.35 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.40 | - | 1 | Nov 23, 2021 | |
| ANNX Annexon | Initiates: Outperform | n/a | $1.88 | - | 1 | Aug 18, 2020 | |
| KZR Kezar Life Sciences | Initiates: Outperform | n/a | $4.70 | - | 1 | Jul 16, 2018 |
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $6.43
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $63.76
Upside: +1.94%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $118.84
Upside: +131.40%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $63.32
Upside: +89.51%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $493.84
Upside: +1.25%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $18.01
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $39.35
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.40
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.88
Upside: -
Kezar Life Sciences
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $4.70
Upside: -